Genelux Corp

Genelux Corp. manufactures and markets drugs and virus strains solutions. It provides drug research, development, and clinical trial services for the healthcare industry. The company was founded by Aladar Szalay in 2001 and is headquartered in Westlake Village, CA.

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

WESTLAKE VILLAGE, Calif., July 10, 2023 (GLOBE NEWSWIRE) -- Genelux Corporation (NASDAQ: GNLX), a late clinical-stage immuno-oncology company, today announced the publication in Frontiers in Immunology of positive results from a Phase 1 trial exploring intrapleural delivered Olvi-Vec in patients with malignant pleural effusion (MPE) due to either MPM or metastatic disease (non-small cell lung cancer or breast cancer). The study was completed at Memorial Sloan Kettering Cancer Center, and the published article is available here.

Genelux Corporation Announces Publication of Phase I Trial Results of Intrapleural Administration of Olvi-Vec in Patients with Malignant Pleural Effusion from Mesothelioma, Lung or Breast Cancers in Frontiers in Immunology

Cava Group, Inc.

Cadrenal Therapeutics Inc

Structure Therapeutics Inc

Renaissance IPO ETF

Lichen China Ltd

Lucy Scientific Discovery Inc

Nft Gaming Co Inc/The

Shengfeng Development Ltd

Skyward Specialty Insurance Group Inc

Wang & Lee Group Inc

Normally, IPO activity gains momentum in the second quarter and peaks in June. This year was no exception.

IPO Round Up of First Half of 2023

- V2ACT Therapeutics™, LLC is a joint venture between Genelux Corporation and TVAX Biomedical, Inc. - V2ACT Immunotherapy is a proprietary immuno-oncology modality composed of Olvi-Vec (oncolytic viral immunotherapy) and TVAX Immunotherapy® (vaccine-enhanced adoptive T cell therapy). - The patent expiry for the combination, prior to any patent term extension, will be in 2036.

Genelux Corporation and TVAX Biomedical, Inc. announce the issuance of a United States patent covering the combination of an adoptive T cell therapy/oncolytic viral cancer treatment that is exclusively licensed to V2ACT Therapeutics™, LLC

WESTLAKE VILLAGE, Calif., June 22, 2023 (GLOBE NEWSWIRE) -- Genelux Corporation (NASDAQ: GNLX), a late clinical-stage immuno-oncology company, today announced that it will be added to the broad-market Russell 3000® Index and small-cap Russell 2000® at the conclusion of the 2023 Russell indexes annual reconstitution, effective after the U.S. equity markets open on June 26, 2023 according to a preliminary list of additions.

Genelux Corporation Set to Join the Russell 3000® and Russell 2000® Indexes Effective June 26, 2023

WESTLAKE VILLAGE, Calif., June 12, 2023 (GLOBE NEWSWIRE) -- Genelux Corporation (NASDAQ: GNLX), a late clinical-stage immuno-oncology company, today announced a private placement for 900,000 shares of the Company's common stock at a purchase price of $20.00 per share, for gross proceeds of approximately $18 million, before deducting offering expenses payable by Genelux. The financing was led by existing investors and no placement agent was involved.

Genelux Corporation Announces $18 Million Private Placement

Genelux focuses on hard-to-treat cancers. Its lead therapy is Olvi-Vec, which did well in a phase 2 trial to treat ovarian cancer.

Why Shares of Genelux Corporation Jumped This Week

WESTLAKE VILLAGE, Calif., May 25, 2023 (GLOBE NEWSWIRE) -- Genelux Corporation (NASDAQ: GNLX), a late clinical-stage immuno-oncology company, today announced the publication of positive topline results from its Phase 2 VIRO-15 trial of Olvi-Vec-primed immunochemotherapy in heavily pretreated patients with platinum-resistant or -refractory ovarian cancer (PRROC) in JAMA Oncology. The article by Holloway et al. was published in print and online and is available here.

Genelux Corporation Announces Publication of Positive Topline Data from Phase 2 VIRO-15 Trial Evaluating Olvimulogene Nanivacirepvec (Olvi-Vec) in Platinum-Resistant or Refractory Ovarian Cancer in the Journal of the American Medical Association (JAMA) On

WESTLAKE VILLAGE, Calif., May 15, 2023 (GLOBE NEWSWIRE) -- Genelux Corporation (NASDAQ: GNLX), a late clinical-stage immuno-oncology company, today announced a private placement of 1,665,247 shares of the Company's common stock at a price of $20.00 per share, for gross proceeds of approximately $33 million, before deducting offering expenses payable by Genelux. Proceeds from the private placement, combined with the current cash and cash equivalents, are expected to extend Genelux' cash runway into the first quarter of 2025. The financing was led by existing investors.

Genelux Corporation Announces $33 Million Private Placement

Amphastar Pharma

Catalyst Pharmaceuticals

Genmab - ADR

Vertex Pharmaceuticals

The top five biotech stocks today have several commonalities: strong ratings. Some also show promising charts and are Tech Leaders.

The Cream Of The Crop: 5 Biotech Stocks That Outrank Most Stocks

GNLX IPO-ed recently, but the company has been around for two decades. The company develops an oncolytic virus targeting cancer.

Genelux: Recent IPO With Phase 3 Stage Oncolytic Virus Cancer Therapy

WESTLAKE VILLAGE, Calif., March 23, 2023 (GLOBE NEWSWIRE) -- Genelux Corporation (NASDAQ: GNLX) (“Genelux” or “the Company”), a late clinical-stage biopharmaceutical company focused on developing a pipeline of next-generation oncolytic viral immunotherapies for patients suffering from aggressive and/or difficult-to-treat solid tumor types, today announced that it will ring the Nasdaq Stock Market (“Nasdaq”) opening bell on Wednesday, March 29, 2023 to commemorate its initial public offering, which occurred in January.

Genelux Corporation to Ring Nasdaq Opening Bell on March 29, 2023

Ambrx Biopharma Inc

Atlas Technical Consultants

Fulcrum Therapeutics Inc

Canoo

LanzaTech Global Inc

NGL Energy Partners

Nektar Therapeutics

FiscalNote Holdings Inc

SelectQuote

Small-cap stocks, in general, are more domestic in nature, and this protects them from geopolitical and foreign exchange risks.

5 Best and Worst Performing Small-Cap Stocks in February 2023

Axcelis Technologies

Arista Networks

Booking Hlds

Innovator IBD(R) Breakout Opportunities ETF

Cadence Design Systems

CECO Environmental Corp

Clean Harbors

Cirrus Logic

ON Semiconductor

Palo Alto Networks

Seagen

Wingstop

As the market indexes fight for support, ANET, WING, BKNG, CDNS, PANW and more land a spot on the IBD Breakout Stocks Index. The post Hot Stocks And Hot Wings Serve Up Spicy Breakouts And Buy Zones appeared first on Investor's Business Daily.

Hot Stocks And Hot Wings Serve Up Spicy Breakouts And Buy Zones

Genelux Corp. priced its initial public offering at $6 a share, the low end of its $6 to $7 a share range, for its stock market debut Thursday on the Nasdaq under the symbol GNLX. With 2.5 million shares in the IPO, the Redlands, Calif.

Genelux IPO prices at bottom of range

WESTLAKE VILLAGE, Calif., Jan. 25, 2023 (GLOBE NEWSWIRE) -- Genelux Corporation (“Genelux” or “the Company”), a clinical-stage immunotherapy company focused on developing a pipeline of next-generation oncolytic viral immunotherapies for patients suffering from aggressive and/or difficult-to-treat solid tumor types, today announced the pricing of its initial public offering of 2,500,000 shares of its common stock at a price to the public of $6.00 per share, for total gross proceeds of approximately $15.0 million, before deducting underwriting discounts and commissions and offering expenses. All of the shares are being offered by Genelux. In addition, Genelux has granted the underwriters a 30-day option to purchase up to an additional 375,000 shares of its common stock at the initial public offering price less the underwriting discounts and commissions.

Genelux Corporation Announces Pricing of Initial Public Offering

Genelux has filed proposed terms for a $16 million U.S. IPO. The firm is developing drug treatments for ovarian and other cancers.

IPO Update: Genelux Finalizes $16 Million IPO Plan

Genelux Corp. GNLX, has set terms for its initial public offering, in which the California-based biotechnology company focused on treating difficult-to-treat tumors could be valued at up to $164.99 million. The company said it is offering 2.5 million shares in the IPO, which is expected to price between $6 and $7 a share, as the company looks to raise up to $17.5 million.

Genelux sets IPO terms, as the biotech could be valued at up to $165 millino

News for Genelux Corp Stock (GNLX)